secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001493152-23-026840
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX amends convertible notes with Juvenescence; deadline for reverse financing extended to Oct 31
--------------------------------------------------------------------------------

- Juvenescence deadline for Reverse subsidiary's >$15M financing extended to Oct 31, 2023 (from prior date).
- Juvenescence may convert outstanding amounts without 19.9% cap if conversion price equals Drawdown Market Price.
- $10M Secured Note principal exchanged for Series B Preferred stock; ~$692,800 of accrued fees remain convertible.
- AgeX drew $500,000 under amended Secured Note on Aug 1, 2023; repayment due Feb 14, 2024.
- Conversion of $10M Note allowed until Oct 31, 2023; after that, only after qualified merger or Mar 13, 2024 (plus 90 days).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223026840/0001493152-23-026840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223026840/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-026840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer